# A Study of Evacetrapib in Participants With Abnormal Cholesterol

> **NCT02168803** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 101 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** Evacetrapib

## Key facts

- **NCT ID:** NCT02168803
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2018-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02168803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02168803, "A Study of Evacetrapib in Participants With Abnormal Cholesterol". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02168803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*